Xiaolin Wang Net Worth

The estimated Net Worth of Xiaolin Wang is at least $3.12 Million dollars as of 17 March 2023. Ms Wang owns over 714 units of Revolution Medicines Inc stock worth over $2,450,150 and over the last 4 years she sold RVMD stock worth over $84,127. In addition, she makes $582,433 as Exec. VP of Clinical Devel. at Revolution Medicines Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms Wang RVMD stock SEC Form 4 insiders trading

Ms has made over 8 trades of the Revolution Medicines Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 714 units of RVMD stock worth $15,551 on 17 March 2023.

The largest trade she's ever made was selling 735 units of Revolution Medicines Inc stock on 19 September 2022 worth over $13,994. On average, Ms trades about 318 units every 53 days since 2021. As of 17 March 2023 she still owns at least 58,813 units of Revolution Medicines Inc stock.

You can see the complete history of Ms Wang stock trades at the bottom of the page.

Ms. Xiaolin Wang biography

Xiaolin Wang is the Exec. VP of Clinical Devel. at Revolution Medicines Inc.

What is the salary of Ms Wang?

As the Exec. VP of Clinical Devel. of Revolution Medicines Inc, the total compensation of Ms Wang at Revolution Medicines Inc is $582,433. There are 8 executives at Revolution Medicines Inc getting paid more, with Mark Goldsmith having the highest compensation of $4,576,250.

How old is Ms Wang?

Ms Wang is 50, she's been the Exec. VP of Clinical Devel. of Revolution Medicines Inc since . There are 12 older and 5 younger executives at Revolution Medicines Inc. The oldest executive at Revolution Medicines Inc is Elizabeth Anderson, 62, who is the Independent Director.

What's Ms Wang's mailing address?

Xiaolin's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Revolution Medicines Inc

Over the last 5 years, insiders at Revolution Medicines Inc have traded over $249,645,422 worth of Revolution Medicines Inc stock and bought 3,371,315 units worth $74,500,278 . The most active insiders traders include Peter Svennilson, Thilo Schroeder, and Rock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,075,216. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth $68,168.

What does Revolution Medicines Inc do?

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Complete history of Ms Wang stock trades at Revolution Medicines Inc

Revolution Medicines Inc executives and stock owners

Revolution Medicines Inc executives and other stock owners filed with the SEC include:

• Mark Goldsmith,
  Chairman of the Board, President, Chief Executive Officer
• Margaret Horn,
  Chief Operating Officer, General Counsel
• Steve Kelsey,
  President of Research and Development
• Dr. Mark A. Goldsmith Ph.D.,
  CEO, Pres & Chairman
• Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.,
  Pres of R&D
• Margaret A. Horn J.D.,
  COO, Gen. Counsel & Sec.
• Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.,
  Pres of R&D
• Margaret A. Horn,
  COO, Gen. Counsel & Sec.
• Xiaolin Wang,
  Exec. VP of Clinical Devel.
• Dr. Mark A. Goldsmith M.D., Ph.D.,
  CEO, Pres & Chairman
• Alexis Borisy,
  Lead Independent Director
• Barbara Weber,
  Independent Director
• Vincent Miller,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Peter Svennilson,
  Independent Director
• Thilo Schroeder,
  Independent Director
• Eric Schmidt,
  Independent Director
• Neil Exter,
  Independent Director
• Jack Anders,
  Vice President - Finance and Principal Accounting Officer
• Dr. Martin D. Burke M.D., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Jack Anders,
  Sr. VP of Fin. & Principal Accounting Officer
• Luan M. Wilfong,
  Sr. VP of HR
• Walter Reiher Ph.D.,
  Chief Information Officer
• David L. Pompliano,
  Founding Chief Scientific Officer
• Dr. Kevan M. Shokat,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Michael A. Fischbach,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Martin D. Burke,
  Co-Founder & Chairman of Scientific Advisory Board
• Frank Clyburn,
  
• Group Iii, Lpcolumn Group I...,
  
• Laurence Lasky,
  Director
• Group Iii, Lp Svennilson Pe...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iv, L.P.Third...,
  
• James E Deerfield Mgmt Iv, ...,
  
• Lin Wei,
  Chief Medical Officer
• Jeff Cislini,
  General Counsel
• Stephen Michael Kelsey,
  See Remarks
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Xiaolin Wang,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Sushil Patel,
  
• Flavia Borellini,
  
• Lorence H. Kim,